Friday, 16 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 5, 2026

Customer Data Platform Company Evaluation Report 2025: Salesforce, Oracle and Adobe Lead with AI-Driven Customer Insights, Real-Time Data Integration and Privacy-First Personalization

View original at finance.yahoo.com
Customer Data Platform Company Evaluation Report 2025: Salesforce, Oracle and Adobe Lead with AI-Driven Customer Insights, Real-Time Data Integration and Privacy-First Personalization Company Logo The Customer Data Platform Companies Quadrant offers an in-depth analysis of the global Customer Data Platform (CDP) market…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The global customer data platform market is projected to witness substantial growth between 2025 and 2030

    80% confidence
  • Advancements in AI and machine learning are expected to further accelerate the expansion of the CDP market

    80% confidence
  • Over 100 companies were evaluated with the top 25 recognized as quadrant leaders in the Customer Data Platform market

    80% confidence
  • High setup and integration costs hinder CDP adoption among mid-sized companies

    80% confidence
  • A customer data platform (CDP) is a technology solution that consolidates customer data from various channels, systems, or sources into a unified, real-time customer profile

    80% confidence
  • AI-powered CDPs can drive hyper-personalization

    80% confidence
  • Third-party cookie deprecation is accelerating the shift toward first-party data via CDPs

    80% confidence
  • Accurately resolving identities across devices and sessions remains technically complex

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
Customer Data Platform Company Evaluation Report 2025: Salesforce, Oracle and Adobe Lead with AI-Driven Customer Insights, Real-Time Data Integration and Privacy-First Personalization — Source | Via News | ViaNews EU